Zacharias Zidianakis

Learn More
Humoral immune responses against the "Cancer-Testis" (CT) antigen NY-ESO-1 are frequently observed in patients with NY-ESO-1 expressing tumors. This is in contrast to other known tumor antigens (TA) defined by antibody or cytotoxic T cell (CTL) reactivity, i.e., MAGE-1, MAGE-3, SSX2, Melan A, and tyrosinase. No NY-ESO-1 antibody has been detected in healthy(More)
Peptides derived from human tumor antigens have been used in a number of clinical trials to induce specific immune responses against autologous tumors in cancer patients. Although favorable clinical results were observed in single patients, immune responses correlating with tumor regression were either not detected or in case of responses, the T-cell(More)
BACKGROUND There is some evidence that neoplastic development and progression evolve through a multistep process associated with hyperproliferation and genetic alterations. Therefore, changes of proliferation and of cellular DNA content within the adenoma-carcinoma sequence were studied. METHODS Using a "mapping" procedure, 12 adenomas and 18 carcinomas(More)
Introduction: Concurrent perspectives in nursing believe that the nurse-patient intimacy is central to patient health, well-being and recovery. Patients’ healing and positive therapeutic outcomes believed to be essentially related to the level of intimacy between the nurses and patients. However, despite the imperative theoretical discussion of intimacy and(More)
  • 1